Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
about
Reproducibility of results in preclinical studies: a perspective from the bone fieldThe role of RANK-ligand inhibition in cancer: the story of denosumabEffect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexateA model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKLEffects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in ratsReceptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patientsrDrak1, a novel kinase related to apoptosis, is strongly expressed in active osteoclasts and induces apoptosis.The receptor activator of nuclear factor-kappaB ligand inhibitor osteoprotegerin is a bone-protective agent in a rat model of chronic renal insufficiency and hyperparathyroidism.The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys.siRNA knock-down of RANK signaling to control osteoclast-mediated bone resorption.Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.Mechanisms balancing skeletal matrix synthesis and degradation.Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.Osteoblast apoptosis and bone turnover.Current treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisEstrogens and Androgens in Skeletal Physiology and Pathophysiology.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Femoral and vertebral strength improvements in postmenopausal women with osteoporosis treated with denosumab.Osteoprotegerin.Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts.Mammary gland-specific expression of biologically active human osteoprotegerin in transgenic miceBone destruction in arthritis.Osteoclasts from patients with autosomal dominant osteopetrosis type I caused by a T253I mutation in low-density lipoprotein receptor-related protein 5 are normal in vitro, but have decreased resorption capacity in vivoC/EBPβ mediates osteoclast recruitment by regulating endothelial progenitor cell expression of SDF-1α.CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerinInfections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?Soluble receptors for advanced glycation end products and receptor activator of NF-κB ligand serum levels as markers of premature labor.Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.RNA therapeutics targeting osteoclast-mediated excessive bone resorption.Osteoprotegerin Induces Apoptosis of Osteoclasts and Osteoclast Precursor Cells via the Fas/Fas Ligand PathwayEvidence that the kinase-truncated c-Src regulates NF-κB signaling by targeting NEMO.OPG Treatment Prevents Bone Loss During Lactation But Does Not Affect Milk Production or Maternal Calcium Metabolism.Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility.Bone matters in lung cancer.B cells and osteoblast and osteoclast development.Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases.Inhibition of RANKL as a treatment for osteoporosis: preclinical and early clinical studies.Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss.The role of the bone microenvironment in skeletal metastasis.
P2860
Q24289530-3CEA22FF-95D1-40EE-858D-7199DDF7D440Q24633284-B3EFDAD6-8375-4F19-AD76-848F9A7BF147Q24658507-3E2A8389-061A-4C49-84D8-7CE2CC2370EDQ24799036-77A583C9-0FDC-4D34-A460-A3BE5852E61CQ28578007-86D44AB2-5456-4580-B69C-E62C3D1A70E5Q28740575-6B9B92E9-5ABA-4B09-A32B-42253F82D44CQ30661731-949986B7-2930-4672-9B6B-362BC622131AQ33229834-A302655C-80C0-4D75-B9C9-0508FCFE4C05Q33279942-04B8F3AA-2BF8-4225-8A3A-CF63A864546AQ33912421-17CA4EA6-01AF-4D8A-92FA-E85C469E2FE2Q34017216-C395F671-C025-4F22-8987-7B898CDB7735Q34129759-19145E68-25E9-46D8-B4EF-EA573B565862Q34272056-618AC08C-B404-4E75-A801-0E999A729FEEQ34274481-7A5F2FC4-8F15-4209-A730-FDCC2C987E74Q34448130-43E44309-8A8B-476D-AA4B-066B6FC6A4BBQ34543980-156B9388-1431-4109-94B2-00D886E3EABFQ34545263-405FD47D-9785-460D-B2F6-1BBD15D19717Q34548650-ED570A4B-45FA-4F7D-B8F0-D676C7A64E2BQ34560598-87393013-3662-4934-8181-B6D03B213EB5Q34790320-40C8C547-9FF2-408A-9B67-9781D06F6626Q34804245-3E6C6B60-FCAA-49DB-9C8E-D4A23E94A45CQ34963176-27C1C3FD-C859-4074-A45A-15194C330BFEQ35085402-4490C29F-E098-4645-8C3D-1D04576D28E2Q35117648-10B5EBEC-BED9-44CC-982A-3CF552C62AC2Q35597152-9C9FADE4-DC40-4240-927F-C3B1E280D2D8Q35643989-1E98918E-F713-414F-8DBF-608BF32291F7Q35658848-F21936B8-40DD-44B5-9E39-37DAD4E21B2EQ35789185-C39DFB44-C827-4F48-B760-79A50C3B7B6FQ35800463-416FF0CF-835C-4494-A179-4BD4E73AEA13Q35842259-A46B5273-8890-4AEB-A8A3-B4C5CA5D0931Q35860261-6EFE38BA-EB21-45C6-A92B-8DCA2D9653EDQ35878795-810DF339-FE0D-40FF-A276-EE903190143DQ36058895-C8CF35CA-D674-4FD4-B2CA-A6B7C24839BDQ36182345-132DEEF6-5D8F-4E4B-9B5C-CCC38FBB43CBQ36324944-F3CE91E4-8292-47C3-9942-5E2C5C0F8283Q36366450-9818BEE7-A7C9-477E-B349-07FF8F617E8AQ36389467-8F020CC5-539A-487B-818E-3FBBC06CDEEDQ36417317-91D364B3-1C75-49F9-86DC-5F049652603EQ36480992-0EC619BE-A191-4C14-9631-CCF66BC474FCQ36491430-783F693D-7193-4D66-B645-A3EF34B07641
P2860
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
@en
type
label
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
@en
prefLabel
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
@en
P2093
P2860
P1476
Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo.
@en
P2093
A J Polverino
F Fletcher
P2860
P304
P356
10.1016/S0002-9440(10)64556-7
P407
P577
2000-08-01T00:00:00Z